ライフサイエンスコーパス: median survival

1 oss all age and EF groups had markedly lower median survival.

2 was associated with worsening FEV1 and lower median survival.

3 hibition of tumor growth and prolonged mouse median survival.

4 with rapid onset of tetraparesis and shorter median survival.

5 ete tumour remission or an increase in their median survival.

6 n adult primary brain tumor and has a dismal median survival.

7 h more than 1 year of difference in observed median survival (0.49-1.79 years).

8 least one intensive procedure) had a shorter median survival (0.7 versus 2.1 years; P<0.001), spent a

9 SOD1(A4V) survival probability (median survival 1.2 years) was significantly decreased c

10 e with wild-type tumors, CRT did not prolong median survival (1.3 v 1.8 years; HR, 1.14; 95% CI, 0.63

11 survival, 14.2 (13.1-15.4) years; and HLA-no median survival, 12.1 (10.9-13.3 years) years; P<0.01, l

12 s (median survival=40days), cisplatin alone (median survival=12days) or saline-treated controls (medi

13 ypermetabolism was associated with a reduced median survival [14.6 compared with 21.4 mo, respectivel

14 nfidence interval, 14.0-20.2) years; HLA-low median survival, 14.2 (13.1-15.4) years; and HLA-no medi

15 70%, P<0.01), and a trend for longer overall median survival (15.4 versus 9.3 months, P=0.72) yet not

16 265 days), compared with unvaccinated mice (median survival, 150 days; P = .002), mice given only LM

17 50 days; P = .002), mice given only LM-Kras (median survival, 150 days; P = .050), and unvaccinated m

18 tated and worst in triple-negative patients: median survival, 16 vs 2.3 years (HR, 5.1; 95% CI, 3.2-8

19 ee of HLA donor-recipient matching: HLA-high median survival, 17.1 (95% confidence interval, 14.0-20.

20 nd unvaccinated mice depleted of Treg cells (median survival, 170 days; P = .048).

21 roup than in the total pancreatectomy group (median survival 19 months vs 4 months, respectively).

22 MM patients without prior knowledge of MGUS (median survival, 2.1 years), although MM patients with (

23 0.77-0.96; P < .01) better overall survival (median survival, 2.8 years) than MM patients without pri

24 tages (28.5% vs 10.1%; P = 0.002), and lower median survival (20.9 vs 41.0 mos; P = 0.001).

25 HER2-positive subtype displayed the longest median survival (21.0 months); patients with triple-nega

26 urvival was recorded between the two groups (median survival 23.4 months [95% CI 20.9-24.8] with doce

27 ted with improved survival compared with UR (median survival, 26 months v 21 months, respectively; st

28 nged survival and reduced PanIN progression (median survival, 265 days), compared with unvaccinated m

29 survival=12days) or saline-treated controls (median survival=28days).

30 patients with EGFR mutations had the longest median survival (3.51 years; 95% CI, 2.89 to 5.5 years),

31 port cells succumbed to bone marrow failure (median survival, 328 days) characteristic of myelodyspla

32 G2 mutant MDS patients surviving >12 months (median survival 35 vs 50 months; P = .017).

33 atin in conventional un-PEGylated particles (median survival=40days), cisplatin alone (median surviva

34 d rate in Bap1(+/-) mice than in WT animals (median survival, 43 weeks vs. 55 weeks after initial exp

35 cohort of 590 patients with advanced cancer (median survival, 5.4 months), 71% wanted to be told thei

36 antly decreased compared with SOD1(non-A4V) (median survival 6.8 years; p<0.0001, log-rank).

37 ith triple-negative subtype had the shortest median survival (6.0 months).

38 ached </= 0.2 ng/mL compared with > 4 ng/mL (median survival, 60.4 v 22.2 months, respectively; P < .

39 raft survival in patients with IPF (adjusted median survival, 65.2 months [interquartile range {IQR},

40 roduced acute leukemia with a short latency (median survival, 67 days).

41 001) but not in patients with COPD (adjusted median survival, 67.7 months [IQR, 25.2-89.6 months] vs

42 ival compared with vehicle-treated controls (median survival, 7.8 vs. 4.5 mo; P = 0.001).

43 io was 0.98 (95% CI, 0.80 to 1.20; P = .847; median survival, 70 months) for SOC + Cel and 0.86 (95%

44 Cel and 0.86 (95% CI, 0.70 to 1.05; P =.130; median survival, 76 months) for SOC + ZA + Cel.

45 is than those without severe disease (n=113; median survival 8.0 years, 95% CI 6.5-9.5 vs 10.3 years,

46 hospitalization and survival was 17.7% with median survival after discharge being 20.6 months.

47 he remaining 56 patients was 32 months, with median survival after discontinuation of 14 months.

48 Median survival after first disease recurrence was 27.7

49 pitalization; 8.8% survived the efforts, and median survival after leaving the hospital was 10.5 mont

50 Median survival after MHS onset was 28 months (range, 3

51 Median survival after R0 resection was similar in the ex

52 Median survival among all patients was 21.1 months [95%

53 Median survival among the entire cohort with brain metas

54 as been demonstrated to significantly extend median survival and achieve a high rate of complete tumo

55 Kaplan-Meier estimates of median survival and descriptive statistics were used to

56 ear relationship identified between expected median survival and EOR argues against a surgical manage

57 the five BMI categories was graded based on median survival and prognostic significance.

58 ctors associated with survival to discharge, median survival, and discharge disposition.

59 homa in mice at seemingly similar paces with median survival around 10 and 11 weeks, respectively, co

60 CLL, where have more aggressive disease with median survivals around eight years.

61 nt to normal level, and significantly longer median survival as compared to free drugs or untargeted

62 rosis (IPF) is a devastating disease, with a median survival as short as 3 years from the time of dia

63 g patients with decompensated cirrhosis, the median survival benefit was 31 days, and it was not cost

64 This therapy extended median survival by 50% and delayed hindlimb paralysis, w

65 codeleted tumors, there was no difference in median survival by treatment arm (2.6 v 2.7 years; HR =

66 re typically have more indolent disease with median survivals close to 25 years, and Ig-mutated CLL,

67 , hospital stay, perioperative mortality, or median survival compared to the younger group.

68 ion and resulted in twice the improvement in median survival compared with T-DM1 alone.

69 Above 1 MBq, the median survival decreased linearly with injected activit

70 lidomide-based therapy results in subsequent median survival exceeding 5 years; for these patients, F

71 Median survival follow-up was 3.84 years (IQR 3.60-4.24)

72 Median survival following a recurrence was 21 months (ra

73 -) and Cd74(-/-) mice demonstrated decreased median survival following hyperoxia compared to WT mice.

74 Median survival following RT was 3.5 months (95% CI, 0.3

75 Median survival for glioblastoma (GBM) remains <15 month

76 The median survival for glioblastoma patients is 15 months

77 The median survival for glioblastoma patients is ~15 months

78 The median survival for HIV patients who underwent biopsy in

79 The median survival for SCLC remained 7 months, and the 12-m

80 The overall median survival for the cohort in the present study was

81 Median survival for the groups treated with phosphate-bu

82 nally related to the underlying CLL, and the median survival for these patients is approximately 1 ye

83 The median survival for TRG 1 was 71 months compared with 30

84 the GI tract to treat, associated with poor median survivals for metastatic disease and significant,

85 the age- and sex-matched control population; median survivals for patients younger than 60 years are

86 ficantly impaired tumor growth and prolonged median survival from 13 d (phosphate-buffered saline) to

87 these mice was associated with an increased median survival from approximately 5.5 to 7.5 mo and inc

88 o percent of patients required dialysis, and median survival from commencement of dialysis was 5.2 ye

89 However, median survival from cure is excellent at about 40 years

90 Estimated median survival from diagnosis until LT or PSC-related d

91 om onset was 9.8 years (95% CI 8.8-10.7) and median survival from enrolment was 1.8 years (0.9-2.7).

92 None developed KSHV-MCD; 6 died with median survival from KICS diagnosis 13.6 months.

93 Median survival from relapse was 28 months.

94 Median survival from study entry was similar for women (

95 Median survival from symptom onset was 9.8 years (95% CI

96 There was a significant increase in overall median survival from the 1970s to 2000s (2 vs. 8 months;

97 rutinib for up to 3 months, with 19.8 months median survival from the time of progression.

98 Overall median survival from the time of the PET/CT study was 48

99 Median survival from time of recurrence to death was 21

100 Median survival gains of 1.5 months were observed.

101 ups treated with 3.7 and 7.4 MBq exhibited a median survival greater than 300 and 227 d, respectively

102 % of patients with metastatic melanoma, with median survival > 3 years.

103 centration AgNP has no negative influence on median survival; however, these flies appeared uniformly

104 Median survival improved with dietary pancreatic enzyme

105 Median survival in patients staged as T3, N0 by the 7th

106 Median survival in patients with only 1 PLN was 31.1 mon

107 Median survival in the metformin group was 5 months, com

108 a small-molecule antagonist of CCR4 improved median survival in the model.

109 Observed median survival in the training and internal validation

110 Observed and predicted median survival in the training and internal validation

111 ive-intent surgical resections, resulting in median survival in this subgroup that exceed 5 years.

112 method, which shows significant extension of median survival in two patient-derived BTIC xenograft mo

113 Among the 21372 patients, the median survival increased from 20 months (1988-1991) to

114 Median survival increased with each quartile increase in

115 ents, further treatment options are limited, median survival is <6 months, and consideration should b

116 ression and hinders effective treatment; the median survival is 16 mo despite standard-of-care therap

117 Even with optimal treatment, median survival is less than 6 months for patients with

118 Median survival is less than 6 months.

119 The median survival is only 5 mo, and the 1-y survival is le

120 omatic, and this, in combination with a long median survival, led to the initial studies of observing

121 is highly invasive and uniformly fatal, with median survival<20months after diagnosis even with the m

122 The median survival, measured from biopsy diagnosis, was 46.

123 Because of their relatively long overall median survival, more aggressive treatments are typicall

124 elivered in brain penetrating nanoparticles (median survival not reached; 80% long-term survivors) co

125 yndrome (SS) are aggressive lymphomas with a median survival of 1 to 5 years.

126 advanced cancer diagnosis for patients with median survival of 1 year or less, and progressive disea

127 ients was 4.9 years (range 0.3-39.6), with a median survival of 11.4 years.

128 rtality of 44.4/100 person-years (PYs) and a median survival of 13.5 months after the diagnosis of CM

129 adiation and chemotherapy, only results in a median survival of 14 months, underscoring the importanc

130 chemotherapy, the prognosis is poor, with a median survival of 16 to 19 months and poor quality of l

131 nary fibrosis is a fatal lung disease with a median survival of 2 to 5 years.

132 ith high risk of metastasis and an estimated median survival of 2.9 y.

133 lastic leukemia at 100% incidence and with a median survival of 21 wk.

134 e severely impaired cardiac function, with a median survival of 22 wk, despite otherwise unaltered sy

135 for 23% of all cases, was associated with a median survival of 23 months and a platinum resistance r

136 A total of 151 had NAFLD and 94 AFLD with median survival of 24 years and 20 years, respectively (

137 of 2.7/100 PYs (P < 0.001) and an estimated median survival of 27.0 years after the diagnosis of CMV

138 ts receiving surgical therapy (n = 25) had a median survival of 27.8 months, significantly superior t

139 poorer survival than the rest of the cohort (median survival of 28 vs 163 months, log-rank test P<0.0

140 and these tumors proliferate rapidly with a median survival of 28-days accompanied with histological

141 (firefighters/police) was associated with a median survival of 28.6% (range, 9.0-76.0).

142 ts experience frequent relapses resulting in median survival of 3 to 5 years, requiring more efficien

143 erative disorder with a poor prognosis and a median survival of 3 years.

144 s who received a DT of more than 55 Gy had a median survival of 32.8 mo, compared with 7.2 mo in pati

145 scharge after OHCA treated with PAD showed a median survival of 40.0% (range, 9.1-83.3).

146 a platinum resistance rate of 63%, versus a median survival of 46 months and platinum resistance rat

147 6 patients developed progressive CLL, with a median survival of 51 months after disease progression.

148 associated with the highest survival with a median survival of 53.0% (range, 26.0-72.0), whereas def

149 adliest cancers in western countries, with a median survival of 6 months and an extremely low percent

150 has resulted in marrow CR rates of 55% and a median survival of 6 to 7 months when given to patients

151 n overall response rates of 40% to 50% and a median survival of 6.5 months in a similar refractory-re

152 studied for the creation of the DS-GPA had a median survival of 7 months from the time of initial tre

153 atients (<10 points) demonstrating excellent median survival of 70.6 months, significantly superior t

154 There were 32 deaths with a median survival of 74.5 months and a 5-year survival rat

155 arise rapidly in this model that displays a median survival of 76 days.

156 those who preferred inotropes over LVAD had median survival of 9.0 months (interquartile range, 3.1-

157 and increased risk of death due to lymphoma (median survival of 9.5 years with BCL2 mutations vs 20.4

158 Importantly, the median survival of AAV9 treatment groups (316-576 days)

159 Median survival of all patients was 10.6 years, and 68 p

160 Ctbp2 heterozygosity increased the median survival of Apc(min/+) mice from 21 to 48 weeks,

161 rity of SMZLs show an indolent course with a median survival of approximately 10 years, nearly 30% of

162 Median survival of children born and diagnosed with CF i

163 espite intensive therapeutic strategies, the median survival of GBM patients has remained dismal over

164 mas (GBMs) are malignant brain tumors with a median survival of less than 18 months.

165 These tumors are highly aggressive with a median survival of less than 2 years.

166 s a mortality rate of approximately 100% and median survival of less than 5 months.

167 studies, (211)At-B10-30F11 RIT improved the median survival of leukemic mice in a dose-dependent fas

168 Median survival of metformin users versus nonusers was 9

169 Furthermore, alisertib extended median survival of mice bearing intracranial human gliob

170 loss of just one allele of Moz increased the median survival of mice by 3.9-fold.

171 with BA and ibrutinib markedly improved the median survival of mice engrafted with the MCL cells.

172 esveratrol treatment significantly increased median survival of mice with HF, lessened cardiac fibros

173 ression in the prostate tumors (n=8); with a median survival of more than 60 days compared to 12 days

174 a and Lung-molGPA scores of 3.5 to 4.0 had a median survival of nearly 4 years.

175 owed significant weight loss, resulting in a median survival of only 24 d.

176 Median survival of patients who had failed treatment fro

177 Incidence proportion and median survival of patients with brain metastases and ne

178 The median survival of patients with idiopathic pulmonary fi

179 The median survival of PET-positive and -negative groups fro

180 The median survival of PET-positive and PET-negative groups

181 Median survival of relapsing patients was 59 months.

182 potent therapeutic effect and prolonged the median survival of TET1-high AML mice over three fold.

183 Median survival of the group was 37 months (6-40).

184 The median survival of the sorafenib-treated patients was 15

185 e 5-year outcomes and to compare survival to median survival of the U.S.

186 40, 95% CI, 0.27 to 0.60, P < .001), and the median survival of those with codeleted tumors treated w

187 s and results in a profound extension of the median survival of treated animals.

188 ies also defines better outcome groups, with median survivals of 15.9 versus 9.2 months (P = 0.029) a

189 o characterize the incidence proportions and median survivals of patients with breast cancer and brai

190 MD treatment was further shown to extend the median survival period from less than 20days in the cont

191 y, culminating in haemorrhagic ascites and a median survival period of 7.5 weeks.

192 Patients' median survival progressively and significantly decrease

193 The percentage of CR and PR correlated with median survival (R = 0.85; P = 0.008).

194 The median survival rate for this disease is 12 months, but

195 In comparison with a median survival rate of 12.9% (interquartile range, 11.1

196 Median survival rates were 43.5, 61, and 71 d for the co

197 (+) T-cell tumor infiltration, and increased median survival, relative to control mice immunized with

198 With increasing numbers of PLN median survival significantly decreased (2-3 PLN: 26.1 m

199 ons: both groups had a significantly shorter median survival than patients with a margin of greater t

200 R1 had higher rates of relapse and a shorter median survival than patients with ovarian cancers that

201 ntinued metformin had a significantly longer median survival than those who discontinued metformin (1

202 rs incidentally diagnosed demonstrate longer median survival than tumors discovered only when the pat

203 iously reported IDEC-131-treated allografts, median survival time (35 +/- 31 days) was significantly

204 cal follow-up showed a significantly shorter median survival time (4.1 y, age-adjusted hazard ratios

205 tment with MPA-loaded nanogels increased the median survival time (MST) of lupus-prone NZB/W F1 mice

206 nvasion and worse disease-specific survival (median survival time 20.3 versus 43.9 months, log-rank P

207 76% in patients who received other regimens (median survival time 223 days).

208 in patients diagnosed in more recent years (median survival time 3.3 years [95% CI 3.0-3.8] in 2001

209 was 65% overall, 48% in the BDex+AA cohort (median survival time 821 days), and 76% in patients who

210 The median survival time after HCC diagnosis for persons wit

211 ediction was assessed by using difference in median survival time and area under the curve with time-

212 r differentiation according to difference in median survival time between high- and low-risk groups (

213 Predicted median survival time calculated according to the Helsink

214 The median survival time for overweight (2.64 y; range: 0.23

215 progressing neurodegenerative disease with a median survival time from diagnosis of 1.5-3 years.

216 levant tissues and a significant increase in median survival time in a dose-dependent manner.

217 amelteon or melatonin significantly improved median survival time in rats (sepsis/melatonin [0.1 mg/k

218 The median survival time in the FOLFOX plus SIRT group was 2

219 Therapy usually fails and the median survival time is < 6 months.

220 The median survival time is 9-12 months, with neither chemot

221 ases (LBDs; majority Parkinson disease [PD]; median survival time not reached).

222 hose with an SUVr of at least 2.5, who had a median survival time of 10.1 (95% CI: 2.4, 15.9; P = .00

223 deaths from lung cancer were documented with median survival time of 10.3 months (interquartile range

224 glioblastoma with a penetrance of 92% and a median survival time of 105 d.

225 nths), 71.6% of patients were deceased, with median survival time of 11 months for those who died.

226 tients with SUVr of less than 1.7, who had a median survival time of 23.1 months (95% confidence inte

227 Survival analysis demonstrated a median survival time of 24 months (95% confidence interv

228 neuromuscular degenerative disorders, with a median survival time of 3-5 years.

229 al pneumonia, is a fatal lung disease with a median survival time of 3-5 years.

230 astoma is a universally lethal cancer with a median survival time of approximately 15 months.

231 The median survival time of breast cancer patients with brai

232 e growth of T24 xenografts and increases the median survival time of nude mice.

233 prevalence of idiopathic pulmonary fibrosis, median survival time of patients, and potential risk fac

234 Median survival time of rats bearing orthotopic glioma w

235 and breast cancer xenografts and doubled the median survival time of TCL1-Tg:p53(-/-) mice, which dev

236 The median survival time of the entire cohort was 9.2 months

237 classical predisposing host factors, and the median survival time was <4 months after diagnosis.

238 low-up of 28.5 months (for living patients), median survival time was 11.8 months (95% CI, 7.4 to 19.

239 The median survival time was 1257 days.

240 The median survival time was 14 months, and the 1- and 2-yea

241 The median survival time was 14 months.

242 after a diagnosis of esophageal cancer, the median survival time was 14.9 months (IQR, 7.1-52.3 mo)

243 The median survival time was 16.3 (11.47-22.57) months, and

244 The median survival time was 16.3 (11.47-22.57) months, and

245 The median survival time was 257 days, but differed consider

246 years [SD 7.2], 54% female, 91% white), the median survival time was 3.8 years (95% CI 3.5-3.8).

247 The median survival time was 35 months, and the most common

248 The median survival time was 82 days (interquartile range [I

249 Median survival time without IRA failure was estimated a

250 estimated the time ratio (relative change in median survival time) per 100 working level months (rado

251 The median survival time, censored to liver transplantation,

252 , as measured by bioluminescent imaging, and median survival time.

253 he Kaplan-Meier method to estimate patients' median survival time.

254 hallenge, ZWC more than doubles the animals' median survival time.

255 ast 8.2% of the subjects in this cohort, and median survival times among men with LOY were 5.5 years

256 h R0, R1 (<1 mm), and R1 (direct) status the median survival times and 5-year survival rates were 41.

257 The differences in median survival times between persons in the lower and u

258 The differences in median survival times between persons in the lower and u

259 with those without diabetes (P < .001), with median survival times of 3 months for long-term diabetic

260 with those without diabetes (P = .02), with median survival times of 9 months for long-term diabetic

261 ligand mismatch significantly prolonged the median survival to 163 d compared with vehicle controls

262 wth inhibition (p=0.001, ANOVA) and enhanced median survival to 27 days over controls.

263 Combined treatment increased median survival to 96 h (range 24-240 h) (p = 0.001), wh

264 iffuse large B-cell lymphoma (DLBCL) reduces median survival to only 1.2 years.

265 0.63 (95% CI 0.50-0.79; one-sided p<0.0001); median survival was 10.6 months (95% CI 9.1-12.1) for re

266 Subgroup median survival was 16.0 months (Folfirinox) vs 16.5 mon

267 Overall, median survival was 2.1 years.

268 Median survival was 2.6 years from diagnosis.

269 Total SOD1 patient median survival was 2.7 years.

270 The median survival was 24 months for the highest risk group

271 The median survival was 3.5 years (interquartile range [IQR]

272 In the positive control CLP group, median survival was 36 h (range 24-48 h).

273 y rate was 5.2%; median LOS was 15 days, and median survival was 38 months.

274 Modeled median survival was 39.4 months for TH and 56.9 months f

275 The median survival was 4.25 months (interquartile range, 1.

276 n follow-up of 40 months (7-109 months), the median survival was 40 months versus 53 months in the AF

277 Median survival was 43, 46 and 84 days, for control, IRE

278 was 20 months (95% CI, 16 to 26 months), and median survival was 49 months (95% CI, 40 months to not

279 Median survival was 5.8 years in the continuous-therapy

280 Median survival was 6.8 months.

281 ontrol arm deaths (83% prostate cancer), and median survival was 66 months.

282 Overall median survival was 9 months, and the principal cause of

283 Median survival was assessed by using Kaplan-Meier and l

284 Median survival was calculated by using the Kaplan-Meier

285 c tumor xenograft models, where an increased median survival was documented.

286 l subtype who underwent trimodality therapy, median survival was extended from 14.5 months to 23.4 mo

287 Median survival was improved in HSAs with higher resecti

288 vs. 0% for the paclitaxel only group and the median survival was increased by 86%.

289 Median survival was more than 10 years following EPCS co

290 Median survival was much shorter in Ile107Val and in Val

291 3 [44%] of 1315 in other African countries), median survival was shorter in the other African countri

292 After matching, median survival was significantly longer for extended ch

293 Median survival was significantly longer for vaccinated

294 Median survival was significantly shortened in overt PMF

295 Median survival was worse in the cTACE-B group than in t

296 After PSM, the 3-year survival rates and median survival were 44.9% and 27.2 (95% confidence inte

297 of Mayo patients were followed until death; median survivals were 19.8 years in ET (n = 292), 13.5 P

298 mutant zebrafish have significantly reduced median survival with death occurring 5 days post-fertili

299 Median survival with IP therapy was 61.8 months (95% CI,

300 prostate DKO) exhibited a markedly increased median survival with reduced tumor size and proliferatio